Navigation Links
Oncolytics Biotech(R) Inc. Announces Unit Offering
Date:11/17/2009

and the other documents that the Company has filed with the United States Securities and Exchange Commission for more complete information about the Company and this offering.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration of qualification under the securities laws of any state or jurisdiction.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the pricing, timing and placement of units, common stock and warrants; the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2009 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such ris
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
3. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
5. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
7. Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date
8. Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
9. Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call
10. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
11. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , 27. März 2015  Peter ... in Biomedical Science für seine bahnbrechende Arbeit ... zwischen Zellkompartimenten transportiert werden, sowie für die ... zur Reaktion auf Stress nutzen, der mit ... Walter ist Professor für Biochemie an der ...
(Date:3/27/2015)... 27, 2015  Peter Walter was chosen as winner ... pioneering work on how proteins are transported between cellular ... mechanism that cells use to handle stress tied to ... professor of biochemistry at the University of California, San ... range of human diseases related to defective protein folding ...
(Date:3/27/2015)...  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , today reported financial ... 31, 2014.  The Company reported a ... for the three months ended December 31, 2014.  This ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 PRC Clinical, ... announced today several management and executive appointments effective immediately. ... Financial Officer (CFO) and member of the Board of ... Business Operations, and Sue Dowden will assume the position ... and current Chief Operations Officer (COO), has been appointed ...
Breaking Biology Technology:Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3
... ... and cytokine-related research tips and information. , ... Piscataway, NJ (PRWEB) May 20, 2010 -- ... the world’s leading interferon expert for life science researchers, has launched a revamped ...
... , CAMBRIDGE, Mass. , May 19 Idenix Pharmaceuticals, Inc. (Nasdaq: ... the 2010 Citi Annual Global Health Care Conference on Wednesday, May 26, 2010 ... New York City and at the Jefferies 2010 Global Life Sciences Conference on ... Hyatt hotel, New York City . , ...
... May 19, 2010 Amsterdam Molecular,Therapeutics (EuroNext Amsterdam: AMT), ... non-audited business update in compliance with,the EU transparency directive. This report ... 2010. , , Q1 2010 Highlights, ... - Dossier validated by EMA on January 20, 2010, ...
Cached Biology Technology:Web Resource for Interferon Research 2Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 2AMT Provides Business Update for the First Quarter 2010 2AMT Provides Business Update for the First Quarter 2010 3
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... A joint study published in Cell by ... for Research in Biomedicine (IRB Barcelona) and the Institute ... Dolf Weijers at the University of Wageningen, in the ... called auxins activate multiple vital plant functions through various ...
... This news release is available in German . ... the death of thousands of neurons in the brain. Nerve growth ... of the neurons; however, clinical tests with GDNF have not yielded ... Neurobiology in Martinsried and their colleagues have now succeeded in demonstrating ...
... of Vitamin A used by teenagers to combat acne might ... an international team of researchers have found that it may ... with autoimmune disorders or those who have received transplants. This ... Journal of Leukocyte Biology . "The ...
Cached Biology News:Scientists unveil a molecular mechanism that controls plant growth and development 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 3Vitamin A used in acne medicines may help autoimmune and transplant patients 2
...
... The new IKATUBE ULTRA TURRAX Tube Disperser ... closed homogenizing system. It offers a cleaner, safer, ... IKATUBE system processes sample volumes from 2 to ... sample type, researchers can choose one of 4 ...
...
... Triple-angle light scattering detector for ... digital signal processing hardware for two ... UV detectors. Also contains an analog ... interfacing to strip chart recorders. Includes ...
Biology Products: